Device Firms Eye Rocketing Pay-For-Performance Insurance Plans Warily
This article was originally published in The Gray Sheet
Executive Summary
Industry group AdvaMed says it is concerned a rapid shift toward pay-for performance and financial risk-sharing models by commercial insurers will discourage providers from giving patients newer devices and could stifle innovation.
You may also be interested in...
Medicare’s ACO Final Rule Responds To Provider Concerns, But Leaves Device Industry Dissatisfied
Although CMS’ newly finalized rule on accountable care organizations has allayed health care providers’ fears of a program too burdensome to bother with, medical device manufacturers remain worried that ACOs will curb patient access to their products.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.
Biden Administration Is Setting An Example For Safe AI Use In Federal Organizations
A new memorandum by the Director of the Office of Management and Budget initiated a government-wide policy that will appoint AI officers to all agencies to address risks for AI use and serve as an example for greater AI adoption.